Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS

L.F. van der Voort, A. Vennegoor, A. Visser, D.L. Knol, B.M.J. Uitdehaag, F. Barkhof, C.B.M. Oudejans, C.H. Polman, J. Killestein

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Scopus)


Objective: To determine if myxovirus resistance protein A (MxA) mRNA is related to clinical disease activity in multiple sclerosis (MS). Methods: Baseline MxA mRNA levels were measured in a prospective cohort of 116 untreated patients with early MS and were related to clinical relapses and MRI at baseline and at follow-up. Results: Low levels of MxA mRNA were associated with the occurrence of relapses (p = 0.002) and contrast-enhancing lesions (CELs) on baseline MRI (p = 0.045). In addition, high baseline MxA mRNA levels were related to a longer time to a first new relapse (hazard ratio [HR] 0.59; 95% confidence interval [CI] 0.35-1.00; p = 0.044). Adding the absence of CELs to high MxA mRNA, the predictive value increased (HR 0.35; 95% CI 0.17-0.74; p = 0.006), clearly showing a cumulative value for combining both factors. Conclusions: MxA mRNA is related to clinical exacerbations, the number of CELs on MRI, and is indicative for the time to a subsequent relapse. If confirmed, MxA mRNA has potential as a biomarker for clinical disease activity in MS. © 2010 by AAN Enterprises, Inc. All rights reserved.
Original languageEnglish
Pages (from-to)1228-1233
Issue number14
Publication statusPublished - 2010

Cite this